Primäre und sekundäre glomeruläre Erkrankungen

Schlüsselwörter

Minimal Change Disease - Membranöse Glomerulonephritis - IgA-Nephropathie - ANCA-assoziierte Glomerulonephritis - Lupusnephritis

Keywords

minimal change disease - membranous glomerulonephritis - igA nephropathy - ANCA-associated glomerulonephritis - lupus nephritis

Literatur

• 1 Basu N, Erwig L P. The antineutrophil cytoplasmic antibody-associated vasculitides. Pathophysiological importance of antineutrophil antibodies in vasculitis.  Curr Opin Hematol. 2010; Oct 21 [Epub ahead of print]; 
• 2 Beck Jr L H, Bonegio R G, Lambeau G. et al . M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.  N Engl J Med. 2009;  361 11-21
• 3 Coppo R, Amore A, Peruzzi L, Vergano L, Camilla R. Innate immunity and IgA nephropathy.  J Nephrol. 2010;  23 626-632
• 4 D’Cruz D P, Khamashta M A, Hughes G R. Systemic lupus erythematosus.  Lancet. 2007;  369 587-596
• 5 Eitner F, Ackermann D, Hilgers R D, Floege J. Supportive Versus Immunosuppressive Therapy of Progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol.  J Nephrol. 2008;  21 284-289
• 6 Jones R B, Tervaert J W, Hauser T. et al . Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.  N Engl J Med. 2010;  363 211-220
• 7 Kamanamool N, McEvoy M, Attia J. et al . Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis.  Medicine (Baltimore). 2010;  89 227-235
• 8 Manno C, Torres D D, Rossini M, Pesce F, Schena F P. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.  Nephrol Dial Transplant. 2009;  24 3694-3701
• 9 Markowitz G S, D’Agati V D. Classification of lupus nephritis.  Curr Opin Nephrol Hypertens. 2009;  18 220-225
• 10 McCarthy E T, Sharma M, Savin V J. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.  Clin J Am Soc Nephrol. 2010;  5 2115-2121
• 11 Pozzi C, Andrulli S, Pani A. et al . Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy.  J Am Soc Nephrol. 2010;  21 1783-1790
• 12 Ronco P, Debiec H. Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy.  J Am Soc Nephrol. 2010;  21 564-569
• 13 Seo P, Stone J H. The antineutrophil cytoplasmic antibody-associated vasculitides.  Am J Med. 2004;  117 39-50
• 14 Stahl R, Hoxha E, Fechner K. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation.  N Engl J Med. 2010;  363 496-498
• 15 Stone J H, Merkel P A, Spiera R. et al . Rituximab versus cyclophosphamide for ANCA-associated vasculitis.  N Engl J Med. 2010;  363 221-232
• 16 Tang S C, Tang A W, Wong S S. et al . Long-term study of mycophenolate mofetil treatment in IgA nephropathy.  Kidney Int. 2010;  77 543-549